https://www.selleckchem.com/pr....oducts/trastuzumab.h
The willingness-to-pay (WTP) threshold was set at $50,000 per year of quality-adjusted PFS. The laparoscopy strategy led to additional costs (average additional cost $7034) but was also more effective (average 4.1months of additional quality-adjusted PFS). The incremental cost-effectiveness ratio (ICER) of laparoscopy was $20,376 per additional year of quality-adjusted PFS. The laparoscopy strategy remained cost-effective even as the cost added by laparoscopy increased. The benefit of laparoscopy was influenced by mitigation of seri
Like
Comment
Share
